Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 1
1985 1
1991 2
1995 1
1999 1
2000 1
2001 1
2002 3
2003 3
2004 6
2005 16
2006 9
2007 11
2008 22
2009 25
2010 25
2011 25
2012 19
2013 20
2014 30
2015 19
2016 19
2017 26
2018 33
2019 29
2020 36
2021 56
2022 46
2023 37
2024 48
2025 30
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

541 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE Study.
Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Shao J, Krol Y, Gottlieb AB. Ogdie A, et al. Among authors: mease pj. Arthritis Rheumatol. 2026 Feb 11. doi: 10.1002/art.70092. Online ahead of print. Arthritis Rheumatol. 2026. PMID: 41670439
Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials.
Gladman DD, Eder L, Selmi C, Mease PJ, Ogdie A, Lozenski K, Adamson E, Sharaf M, Rampakakis E, Pina Vegas L, Coates LC. Gladman DD, et al. Among authors: mease pj. Rheumatol Ther. 2026 Feb;13(1):213-229. doi: 10.1007/s40744-025-00812-3. Epub 2025 Dec 15. Rheumatol Ther. 2026. PMID: 41396391 Free PMC article.
Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Ogdie A, Middaugh N, Blachley T, Bourgeois T, Ling YL, Mundayat R, Fallon L, Masri KR, Mease PJ. Ogdie A, et al. Among authors: mease pj. Rheumatol Ther. 2026 Feb;13(1):195-212. doi: 10.1007/s40744-025-00811-4. Epub 2025 Dec 4. Rheumatol Ther. 2026. PMID: 41343116 Free PMC article.
Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies.
Marzo-Ortega H, Navarro-Compan V, Dubreuil M, Mease PJ, Magrey M, Rudwaleit M, D'Agostino MA, Gaffney K, Kay J, de la Loge C, Massow U, Taieb V, Vaux T, Deodhar A. Marzo-Ortega H, et al. Among authors: mease pj. RMD Open. 2025 Nov 28;11(4):e006013. doi: 10.1136/rmdopen-2025-006013. RMD Open. 2025. PMID: 41314667 Free PMC article. Clinical Trial.
Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors.
Mease PJ, Walsh JA, Fitzgerald TP, Chakravarty SD, Adamson E, Emond B, Rossi C, Schwartzbein S, Yokoji K, Wang Y, Lefebvre P, Pilon D, Singla S, Merola JF. Mease PJ, et al. Adv Ther. 2026 Jan;43(1):255-270. doi: 10.1007/s12325-025-03416-z. Epub 2025 Nov 21. Adv Ther. 2026. PMID: 41269519 Free PMC article.
On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors.
Mease PJ, Walsh JA, Fitzgerald TP, Chakravarty SD, Adamson E, Emond B, Rossi C, Schwartzbein S, Yokoji K, Wang Y, Lefebvre P, Pilon D, Singla S, Merola JF. Mease PJ, et al. Rheumatol Ther. 2026 Feb;13(1):115-134. doi: 10.1007/s40744-025-00804-3. Epub 2025 Nov 14. Rheumatol Ther. 2026. PMID: 41239039 Free PMC article.
Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.
McInnes IB, Coates LC, Mease PJ, Ogdie A, Kavanaugh A, Eder L, Schett G, Kivitz A, McGonagle D, Brennan N, Godwood A, Cullen E, Reich K, Ritchlin CT, Merola JF. McInnes IB, et al. Among authors: mease pj. Nat Med. 2025 Dec;31(12):4160-4171. doi: 10.1038/s41591-025-03971-6. Epub 2025 Oct 6. Nat Med. 2025. PMID: 41053449 Free PMC article. Clinical Trial.
GRAPPA 2024 Annual Meeting: An Update on Major Project Milestones.
Colaco K, Eder L, Grieb SM, Leung YY, Lubrano E, Mease PJ, Perez-Chada LM, Poddubnyy D, Soriano ER, Chandran V. Colaco K, et al. Among authors: mease pj. J Rheumatol. 2025 Dec 1;52(Suppl 3):91-93. doi: 10.3899/jrheum.2025-0839. J Rheumatol. 2025. PMID: 41033821 Free article.
541 results